The latest price target for Evolus (NASDAQ:EOLS) was reported by BTIG on March 4, 2026. The analyst firm set a price target for $13.00 expecting EOLS to rise to within 12 months (a possible 182.61% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Evolus (NASDAQ:EOLS) was provided by BTIG, and Evolus reiterated their buy rating.

The last upgrade for Evolus Inc happened on January 29, 2024 when Barclays raised their price target to $16. Barclays previously had an equal-weight for Evolus Inc.

The last downgrade for Evolus Inc happened on August 6, 2025 when Needham changed their price target from $22 to $22 for Evolus Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evolus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evolus was filed on March 4, 2026 so you should expect the next rating to be made available sometime around March 4, 2027.

While ratings are subjective and will change, the latest Evolus (EOLS) rating was a reiterated with a price target of $13.00 to $13.00. The current price Evolus (EOLS) is trading at is $4.60, which is out of the analyst’s predicted range.